Expression of K Homology Domain Containing Protein (KOC) in Pancreatic Cytology with Corresponding Histology

Toll, Adam D.; Witkiewicz, Agnieszka K.; Bibbo, Marluce

doi:10.1159/000325112

Cited by 14 publications

(16 citation statements)

References 16 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, mild to moderate ductal dysplasia, including intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms with adenoma and/or moderate dysplasia, PanIN1, and PanIN2, does not appear to exhibit IMP3 positivity in either cytology or resected specimens [12,74]. In a limited subset of examined cases, focal ductules in areas of chronic pancreatitis demonstrated weak staining [12,74]. Toll et al [74] demonstrated 100% specificity for diagnosis of pancreatic ductal adenocarcinoma with the use of IMP3 and a sensitivity greater than histology or cytology alone.…”

Section: Pancreaticobiliary Dysplasia and Carcinomamentioning

confidence: 99%

“…In a limited subset of examined cases, focal ductules in areas of chronic pancreatitis demonstrated weak staining [12,74]. Toll et al [74] demonstrated 100% specificity for diagnosis of pancreatic ductal adenocarcinoma with the use of IMP3 and a sensitivity greater than histology or cytology alone. Yantiss et al [12] utilized RT-PCR to assess IMP3 expression in pancreatic ductal carcinomas and nonneoplastic pancreatic tissue and demonstrated that in 15 (78.9%) of 19 cases of pancreatic ductal carcinoma IMP3 mRNA was readily detectable, while IMP3 mRNA was only minimally present in nonneoplastic tissue.…”

Section: Pancreaticobiliary Dysplasia and Carcinomamentioning

confidence: 99%

See 1 more Smart Citation

The use of insulin like-growth factor II messenger RNA binding protein–3 in diagnostic pathology

Findeis‐Hosey

2011

Human Pathology

View full text Add to dashboard Cite

Section: Pancreaticobiliary Dysplasia and Carcinomamentioning

confidence: 99%

Section: Pancreaticobiliary Dysplasia and Carcinomamentioning

confidence: 99%

The use of insulin like-growth factor II messenger RNA binding protein–3 in diagnostic pathology

Findeis‐Hosey

2011

Human Pathology

View full text Add to dashboard Cite

“…Immunohystochemical analysis showed strong staining for KOC protein in invasive pancreatic tissue carcinomas versus normal pancreatic tissue. It was proposed to be a molecular marker with a high sensitivity and specificity in discriminating PDAC from benign ductal epithelium (Toll et al, 2009). …”

Section: Identification Of New Potential Tumor Tissue Biomarkersmentioning

confidence: 99%

Novel Biomarkers in Pancreatic Cancer

Dima¹,

Tănase²,

Albulescu³

et al. 2012

Pancreatic Cancer - Clinical Management

View full text Add to dashboard Cite

“…IHC is a technique widely used in diagnostic pathology that enables the observation and localisation of protein expression simultaneously in tissue and cellular compartments [29]. Diagnostic IHC biomarkers have been investigated both as single biomarkers and as part of biomarker panels to improve the diagnosis of PDAC, but to date none has entered into routine clinical practice [30-37]. We performed a meta-analysis of potential PDAC IHC diagnostic biomarkers [38] aiming to generate a list of biomarkers assessed in either surgical or cytology specimens, where PDAC was compared with normal pancreas and/or chronic pancreatitis.…”

Section: Introductionmentioning

confidence: 99%

Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel

et al. 2014

View full text Add to dashboard Cite

BackgroundPancreatico-biliary adenocarcinomas (PBA) have a poor prognosis. Diagnosis is usually achieved by imaging and/or endoscopy with confirmatory cytology. Cytological interpretation can be difficult especially in the setting of chronic pancreatitis/cholangitis. Immunohistochemistry (IHC) biomarkers could act as an adjunct to cytology to improve the diagnosis. Thus, we performed a meta-analysis and selected KOC, S100P, mesothelin and MUC1 for further validation in PBA resection specimens.MethodsTissue microarrays containing tumour and normal cores in a ratio of 3:2, from 99 surgically resected PBA patients, were used for IHC. IHC was performed on an automated platform using antibodies against KOC, S100P, mesothelin and MUC1. Tissue cores were scored for staining intensity and proportion of tissue stained using a Histoscore method (range, 0–300). Sensitivity and specificity for individual biomarkers, as well as biomarker panels, were determined with different cut-offs for positivity and compared by summary receiver operating characteristic (ROC) curve.ResultsThe expression of all four biomarkers was high in PBA versus normal ducts, with a mean Histoscore of 150 vs. 0.4 for KOC, 165 vs. 0.3 for S100P, 115 vs. 0.5 for mesothelin and 200 vs. 14 for MUC1 (p < .0001 for all comparisons). Five cut-offs were carefully chosen for sensitivity/specificity analysis. Four of these cut-offs, namely 5%, 10% or 20% positive cells and Histoscore 20 were identified using ROC curve analysis and the fifth cut-off was moderate-strong staining intensity. Using 20% positive cells as a cut-off achieved higher sensitivity/specificity values: KOC 84%/100%; S100P 83%/100%; mesothelin 88%/92%; and MUC1 89%/63%. Analysis of a panel of KOC, S100P and mesothelin achieved 100% sensitivity and 99% specificity if at least 2 biomarkers were positive for 10% cut-off; and 100% sensitivity and specificity for 20% cut-off.ConclusionA biomarker panel of KOC, S100P and mesothelin with at least 2 biomarkers positive was found to be an optimum panel with both 10% and 20% cut-offs in resection specimens from patients with PBA.

show abstract

Expression of K Homology Domain Containing Protein (KOC) in Pancreatic Cytology with Corresponding Histology

Cited by 14 publications

References 16 publications

The use of insulin like-growth factor II messenger RNA binding protein–3 in diagnostic pathology

The use of insulin like-growth factor II messenger RNA binding protein–3 in diagnostic pathology

Novel Biomarkers in Pancreatic Cancer

Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel

Contact Info

Product

Resources

About